Targeting immune checkpoints with Programmed cell death protein 1 PD-1/ programmed cell death ligand 1 (PD-L1) pathway inhibitors or blockade of CTLA-4 has proven to be an effective therapeutic approach for various cancers. Here, PDCD1 is linked to cancer.